Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) – Investment analysts at Cantor Fitzgerald increased their FY2019 earnings per share (EPS) estimates for Deciphera Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 14th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn ($4.22) per share for the year, up from their prior estimate of ($4.49). Cantor Fitzgerald has a “Overweight” rating and a $55.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Deciphera Pharmaceuticals’ FY2020 earnings at ($5.25) EPS.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The business had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million.
Shares of DCPH opened at $37.00 on Monday. The stock has a fifty day moving average of $24.47 and a two-hundred day moving average of $24.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The company has a market capitalization of $1.41 billion, a PE ratio of -13.12 and a beta of 2.34. Deciphera Pharmaceuticals has a fifty-two week low of $18.55 and a fifty-two week high of $42.99.
In other news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $36.42, for a total transaction of $12,747,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Lee Flynn sold 148,107 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $40.92, for a total value of $6,060,538.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 534,134 shares of company stock valued at $20,246,496. Insiders own 7.02% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at $6,974,000. BlackRock Inc. increased its holdings in Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after purchasing an additional 311,870 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at $4,337,000. Point72 Asset Management L.P. acquired a new stake in Deciphera Pharmaceuticals in the 2nd quarter valued at $4,606,000. Finally, Alps Advisors Inc. acquired a new stake in Deciphera Pharmaceuticals in the 2nd quarter valued at $1,802,000. Institutional investors and hedge funds own 59.80% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Read More: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.